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Background: Maspin, which is classified as a tumor suppressor protein, is downregulated in many types of cancer.
Several studies have suggested potential anti-proliferative activity of maspin as well as sensitizing activity of maspin
for therapeutic cytotoxic agents in breast cancer tissue culture and animal models. All of the experimental data
gathered so far have been based on studies with maspin localized cytoplasmically, while maspin in breast cancer
tumor cells may be located in the cytoplasm, nucleus or both. In this study, the effect of maspin cytoplasmic and
nuclear location and expression level on breast cancer proliferation and patient survival was studied.
Methods: Tissue sections from 166 patients with invasive ductal breast cancer were stained by immunohistochemistry
for maspin and Ki-67 protein. The localization and expression level of maspin were correlated with estimated patient
overall survival and percent of Ki-67-positive cells. In further studies, we created constructs for transient transfection of
maspin into breast cancer cells with targeted cytoplasmic and nuclear location. We analyzed the effect of maspin
location in normal epithelial cell line MCF10A and three breast cancer cell lines – MCF-7, MDA-MB-231 and
SKBR-3 – by immunofluorescence and proliferation assay.
Results: We observed a strong positive correlation between moderate and high nuclear maspin level and
survival of patients. Moreover, a statistically significant negative relationship was observed between nuclear
maspin and Ki-67 expression in patients with invasive ductal breast cancer. Spearman’s correlation analysis
showed a negative correlation between level of maspin localized in nucleus and percentage of Ki-67 positive
cells. No such differences were observed in cells with cytoplasmic maspin. We found a strong correlation
between nuclear maspin and loss of Ki-67 protein in breast cancer cell lines, while there was no effect in normal
epithelial cells from breast. The anti-proliferative effect of nuclear maspin on breast cancer cells was statistically
significant in comparison to cytoplasmic maspin.
Conclusions: Our results suggest that nuclear maspin localization may be a prognostic factor in breast cancer
and may have a strong therapeutic potential in gene therapy. Moreover, these data provide a new insight into
the role of cytoplasmic and nuclear fractions of maspin in breast cancer.
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Maspin (Mammary Serine Protease Inhibitor) was first
identified in normal mammary glands and breast cancer
cells. Based on structural homology, maspin belongs to
the serpin superfamily (serpin b5) [1]. Since serpin b5
has no inhibitory activity against serine proteases, its
role in cells is not fully understood [2].
In normal mammary glands, maspin is expressed, at a
high level, in myoepithelial cells, while it is not found in
luminal cells [1,3]. Maspin may be located in cytoplasm,
nucleus, at the cell surface and in extracellular matrix of
myoepithelial cells in normal mammary glands [4]. How-
ever, there have been no specific domains or sequences
identified that may ensure maspin nuclear localization
or secretion. Maspin is responsible for cell adhesion and
mobility during embryogenesis and mammary gland de-
velopment [5]. Maspin is also important in the develop-
ment of the mammary gland. At the early stage of
lactation, maspin causes a lower level of milk proteins,
including casein and WAP (whey acidic protein) [6].
Maspin is classified as a class II tumor suppressor.
Maspin demonstrates proapoptotic, antimetastatic and
antiangiogenic properties, exerting an inhibitory effect on
tumor cell survival, mobility, invasiveness and metastasis
ability, and also reduces the tumor tissue vascularization
[7-10]. In many studies, it has been found that a decreased
level of maspin causes cancer progression and transition
from non-invasive to invasive cancer [11,12]. In vitro stud-
ies showed that in primary cell lines derived from tumors
maspin is expressed, while after several passages the mas-
pin level decreases until complete loss [7,13]. In secondary
breast cancer cell lines maspin is absent [14]. Clinical data
indicate a positive correlation between higher maspin ex-
pression level and lower degree of differentiation, lower
grade of tumor and improved survival of patients [10,15].
Despite these data, there are some controversial and
contradictory data about maspin prognostic significance
and importance of its expression. In many cancer stud-
ies, including those related to breast cancer, a negative
and positive correlation are described with reference to
high or low maspin expression level as a prognostic fac-
tor of tumor development [16-19].
Many reports have suggested that biological significance,
activity and clinical implications of maspin in various
types of cancer depend on its subcellular localization
[19-22]. In many types of cancers, including breast, ovar-
ian, lung, larynx, renal and colon cancer, there has been
indicated a positive correlation between nuclear maspin
location and molecular markers of good prognosis, benign
instead of malignant form of cancer, better patient survival
and long-term remission [19,20,23-26]. However, the sig-
nificance of nuclear maspin localization in cancer is still
not clear enough to use maspin localization pattern as an
unquestioned diagnostic or prognostic factor. Maspin’smechanism of action, especially its nuclear fraction, is
not very well understood and requires further examin-
ation for better understanding. Recently, a few attempts
have been made to clarify this controversy of anticancer
activity and molecular mechanism of action of maspin
using different models [22,27-29] but they have not
clarified fully the essential question of the potential dif-
ferent activities of cytoplasmic and nuclear fraction of
maspin, because in studies performed so far maspin
was mainly localized in cytoplasm or ubiquitously in
cytoplasm and cell nucleus [22,30,31].
That is why we made an attempt to develop a breast
cancer tissue culture model system for studies of func-
tion of cytoplasmic and nuclear maspin independently.
This breast cancer cell line model system together with
clinical data from the patients allowed us to resolve the
effect of nuclear and cytoplasmic maspin in breast can-
cer on proliferation and its potential as a genetic drug in
breast cancer gene therapy.
Methods
Patient samples and ethical issues
Breast tumor tissue sections for statistical analysis were
taken intraoperatively from 166 women diagnosed with
invasive ductal breast cancer. For visualization of maspin
location during cancerogenesis (see Figure 1) breast
tumor sections were stained also from material taken
from women diagnosed with other stages of cancer: early
stage of ductal breast cancer, ductal carcinoma in situ,
early stage of invasive breast cancer. Slices of breast
tumor tissue were collected in accordance and with the
recommendations of the: “Bioethical Committee of the
Lower Silesian Oncology Center”. Research was per-
formed on archived, fixed and paraffin-embedded breast
tissue specimens obtained during breast cancer surgery.
According to Polish regulations we do not need to ob-
tain patients consent for studies on archived tissue spec-
imens. Sample processing, data processing and analyses
were performed in full compliance with all bioethical
regulations and in accordance with Polish law. Bioethical
Committee of the Lower Silesian Oncology Center ap-
proved the study.
4% formalin-fixed and paraffin-embedded samples for
histopathological examination were routinely stained
with hematoxylin and eosin. Histological evaluation of
specimens was made by two independent pathologists.
The characteristics of the patients are shown in Table 1.
Adjacent slices of the same paraffin blocks were used for
immunohistochemistry.
Immunohistochemistry
Paraffin sections were placed on Superfrost + slides,
deparaffinized in xylene, rehydrated in a series of de-
creasing concentrations of ethanol and washed in
Figure 1 (See legend on next page.)
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Figure 1 Immunohistochemical staining of breast cancer specimens from patients. Staining for: maspin (a-i) and Ki-67 (j, k); a - maspin
localization in normal human mammary gland; b-f - maspin localization in different stages of breast cancer, as follows: early stage of ductal breast
cancer, ductal carcinoma in situ, early stage of invasive breast cancer, invasive breast cancer (e, f); g-i - subcellular maspin localization in breast
cancer, as follows: nuclear, cytoplasmic, mixed; j - low grading tumor with low percentage of Ki-67 positive cells; k - breast cancer with high
percentage of Ki-67 positive cells in malignant cancer.
Table 1 Patients’ characteristics N = 166
Characteristic N %
Age
< = 50 22 13.3
51–60 42 25.3
61–70 57 34.3
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by boiling in a microwave in citrate buffer (pH 6.0), the
endogenous peroxidase activity was blocked by incubat-
ing sections with 3% H2O2 solution for 30 minutes.
Slices were incubated for one hour at room temperature
with primary antibodies diluted in background reducing
buffer (DakoCytomation): mouse anti-human maspin (clone
G167-7, BD Pharmingen), dilution 1:400 or mouse anti-
Ki-67 (clone MIB-1, DakoCytomation), dilution 1:10.
After washing three times with PBS for 5 minutes, slices
were incubated for 15 min with secondary, biotinylated
antibody, followed by 30 min incubation with streptavidin-
horseradish peroxidase (DakoCytomation). Color was de-
veloped with 3,3′-diaminobenzidine (DAB) for 3-7 minutes.
Nuclei were stained with Mayer’s hematoxylin.
To evaluate maspin expression, a semiquantitative
method [32] was used to determine reaction intensity
and percentage of positive cells from three representa-
tive fields of the specimen at 40× magnification. Speci-
mens were scored according to percentage: 1-5% – 1
point, 6-50% – 2 points, >50% – 3 points and reaction
intensity: weak – 1 point, moderate – 2 points, strong –
3 points. Points for both percentage and intensity were
added and specimens were categorized into four groups:
negative reaction – 0 points (0 points for percentage and
intensity), weak reaction – 1 point (1-2 points), moder-
ate reaction – 2 points (3-4 points), strong reaction – 3
points (5-6 points). Evaluation of maspin expression was
conducted independently for the cytoplasm and the nu-
cleus using the same procedure.
To evaluate the proliferative status, three representa-
tive fields with the typical signal from Ki-67 antigen was
chosen [33]. At 40× magnification, nuclei showing ex-
pression of Ki-67 antigen in relation to all nuclei were
counted. Proliferative status of tumors was evaluated as
the percentage of positive cells and classified into two
groups: less than 20% and more than 20% (according to
the limit value of predictive and prognostic assessment
of Ki-67 expression in breast cancer).
Cell culture
Human breast cancer cell line MCF-7 was cultured in Ea-
gle’s medium (EMEM, Lonza) and MDA-MB-231 and
SKBR-3 cell lines were cultured on Dulbecco’s modified
Eagle’s medium (DMEM with low glucose, Lonza) supple-
mented with 10% fetal bovine serum (Sigma), 1% Glutamax
(Gibco) and 1% antibiotic/antimycotic (Gibco). MCF10Acell line was cultured on DMEM/F12 medium (medium
mixture, Lonza) supplemented with 5% horse serum
(Gibco), 1% Glutamax (Gibco), 1% antibiotic/antimyco-
tic (Gibco), 20 ng/ml epidermal growth factor (Sigma),
0.5 μg/ml hydrocortisone (Sigma), 100 ng/ml cholera
toxin (Sigma) and 10 μg/ml insulin (Sigma). MCF-7
(ATTC HTB-22), SKBR-3 (ATTC HTB-30), MDA-MB-
231 (ATTC HTB-26) and MCF10A (ATTC CRL-10317)
cell lines were kindly provided by Dr Paweł Surowiak
(Wrocław Medical University) and Prof. Hermann Lage
(Institute of Pathology, Charite Campus Mitte, Humboldt
University, Berlin). MCF-7 stable cell lines expressing en-
hanced green fluorescent protein (EGFP) and maspin-
EGFP were cultured in supplemented Eagle’s medium
with G418 antibiotic in a final concentration of 150 μg/ml.
All cell lines were maintained at 37°C in 5% CO2.
Plasmid construction
Control plasmid pEGFP-C1 ensuring expression of
EGFP was purchased from Clontech. Expression vector
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structed based on pReceiver M03 (GeneCopoeia). In order
to obtain nuclear localization of maspin with fusion protein
EGFP, the nuclear localization signal (NLS) was inserted
between the sequences encoding maspin and EGFP. NLS
was inserted by site-directed mutagenesis using Quik-




TGGATGACCGTAAGGAG-3′. The amino acid sequence
of NLS is PKKKRKV.
Stable and transient cell transfection
For generation of stable cell lines expressing EGFP,
maspin-EGFP and maspin-NLS-EGFP, MCF-7 cells were
plated on a 10 cm cell culture dish and after 24 hours
transfected with complexes of plasmid DNA and Meta-
fectenePro (Biontex). Six hours later cell culture medium
was removed and replaced with complete medium and
after 48 hours the post-transfection medium was re-
placed with complete selection medium containing anti-
biotic G418 to a final concentration of 400 μg/ml. The
selection was monitored by EGFP expression and nega-
tive cell death and G418 concentration was gradually
reduced.
For transient transfection to immunofluorescence ana-
lysis breast cancer cells were plated on a 24-well plate
24 hours before transfection. Six hours after transfection
with complexes of MetafectenePro and plasmid DNA
medium was replaced with fresh complete medium.
After appropriate time cells were fixed and stained as
described below.
Immunofluorescence
For immunofluorescence experiments, cells were plated
on glass coverslips, fixed in 4% paraformaldehyde for
20 minutes and permeabilized with 0.5% Triton X-100
in PBS. Fixed cells were incubated in primary antibody
solution overnight at 4°C, washed with PBS, and incu-
bated for 1 hour with secondary antibody solution at
room temperature and washed again in PBS. Coverslips
were mounted on glass slides using DABCO mounting
medium (Fluka) with DAPI. Staining was visualized on a
Zeiss 510 Meta confocal microscope using the 63X ob-
jective. Primary antibodies used for staining were mouse
anti-human maspin (BD Pharmingen, 1:25), mouse anti-
human Ki-67 (DakoCytomation, 1:50), rabbit anti-human
lamin C (a kind gift from prof. C.J Hutchison, 1:20). Sec-
ondary antibodies were donkey anti-mouse conjugated
with TRITC and donkey anti-rabbit conjugated with Cy5
(both from Jackson ImmunoResearch). After 24 hours to
120 hours following transfection, EGFP-expressing cells
were counted for expression of Ki-67 antigen in five to tenfields of view and the Ki-67-positive subpopulation was
calculated as the percentage of all transfected cells.
Cell proliferation assay
For cell proliferation assay cells were plated on a 10 cm
cell culture dish and after 24 hours transfected with com-
plexes of plasmid DNA and MetafectenePro (Biontex).
Medium was replaced every three days with complete
medium (without G418). After 24 hours to 9 days follow-
ing transfection EGFP-expressing cells and all cells were
counted in four fields of view and the EGFP-positive sub-
population was calculated as the percentage of all cells.
Statistical analysis
SPSS software (SPSS version 17.0., Chicago, Illinois, USA)
was used for statistical analysis of histopathological results.
In order to analyze the correlation between the maspin
protein level in cytoplasm and/or nucleus and the presence
of Ki-67 antigen, contingency tables were used. Statistical
significance of differences was assessed using the Pearson’s
chi-square test or, if the assumptions were not met, Fisher’s
exact test estimated with simulation methods. The correl-
ation was evaluated by Spearman’s test. Significance was
defined at the level of P-value ≤0.05 by the two-tailed test.
Overall survival was estimated by the Kaplan-Meier
method. The logrank test (the Mantel-Cox test) was used
to evaluate statistical differences between two curves (for
cytoplasmic pool of maspin and nuclear pool of maspin).
Microsoft Office Excel 2003 was used for statistical
analysis of data obtained from experiments on cell lines.
To evaluate the significance of differences between con-
trol and experimental groups the two-tailed Student’s t
test was used.
Results
Maspin expression and localization in normal and cancer
tissue from breast
In normal breast tissue, maspin is expressed in myoepithe-
lial cells (Figure 1a). During cancer development, there is
a decline in maspin level in myoepithelial cells and maspin
protein is expressed in other cells (Figure 1b-f). Breast
cancer cells showed nuclear, cytoplasmic or mixed maspin
location (Figure 1g-i).
In order to analyze the subcellular location and assess
the level of expression of maspin in normal and tumor
tissues of breast, a collection of tissue sections from 166
patients with invasive ductal breast cancer was studied
using immunohistochemistry. The maspin-specific stain-
ing intensity in ductal breast cancer specimens was com-
pared with staining of myoepithelial cells from regions
of normal mammary tissue (Figure 1a) and cancer in situ
specimens (Figure 1b,c). The staining intensity in myoe-
pithelial cells was generally stronger than in breast can-
cer tissue.
Table 3 Maspin intensity of staining
Maspin staining intensity Cytoplasm Nucleus
Lack 54 (32.5%) 38 (22.9%)
Weak 27 (16.3%) 35 (21.1%)
Moderate 71 (42.8%) 84 (50.6%)
Strong 14 (8.4%) 9 (5.4%)
Machowska et al. BMC Cancer 2014, 14:142 Page 6 of 17
http://www.biomedcentral.com/1471-2407/14/142The intensity and subcellular distribution of maspin
protein were assessed and counted in specimens of
breast cancer tissues. Positive staining for maspin was
observed in 148 cases (89.2%) and lack of this protein in
18 cases (10.8%). In the majority of cases (N = 91; 54.8%)
mixed nuclear and cytoplasmic maspin location was ob-
served. In Tables 2 and 3, the distribution of maspin
staining localization and intensity is shown. These data
indicate that breast cancer specimens showed a hetero-
geneous level of maspin protein as well as various levels
of maspin fraction in cytoplasm and nuclei and that this
heterogeneity of maspin level and location should be
taken into the future considerations and statistical ana-
lyses. Moderate and high levels of nuclear maspin correl-
ate with better prognosis for patients.
Correlation between maspin expression level, location
and proliferation status and prognosis for patients
The data about level of maspin and amount of maspin
in particular subcellular locations were analyzed with re-
spect to patient survival rate as well as proliferation sta-
tus of the cancer cells from patients. The analyses of
expression of Ki-67 protein (typical proliferation marker
used in cancer diagnosis) in particular cells were per-
formed in parallel in order to assess the proliferation sta-
tus of cancer cells (Figure 2c,d) [34,35]. Figure 1, sections j
and k demonstrate low grading tumor and high grading
tumor (according to Nottingham scale) with low and high
percentage of Ki-67 positive cells respectively.
For Kaplan-Meier analyses of survival of patients with
breast cancer, samples were divided into two groups
representing the subcellular status of maspin – cytoplas-
mic or nuclear – and the level of protein in particular
fractions: low level or lack of protein and moderate and
high level of protein (Figure 2a,b). Such organization of
data allowed us to demonstrate the strong positive cor-
relation between high nuclear maspin level and the sur-
vival of patients. Negative prognosis was associated with
high level of cytoplasmic maspin while lack or low level
of cytoplasmic maspin correlated with better prognosis
than high cytoplasmic maspin.
In order to analyze the correlation between maspin lo-
cation and Ki-67 protein expression (proliferation sta-
tus), specimens were divided and categorized into two
groups: less than 20% Ki-67 positive cells (86, 51.8%)
and more than 20% (80, 48.2%) (Figure 2c,d). No signifi-
cant relationship (p = 0.118) was observed betweenTable 2 Maspin localization in patients’ specimens
Maspin localization Number of cases
Mixed 91 (54.8%)
Cytoplasmic 22 (13.3%)
Nuclear 35 (21.1%)cytoplasmic maspin and Ki-67 expression. Moreover,
there was no significant correlation between cytoplasmic
maspin and percentage of Ki-67 positive cells in the two
groups (Spearman’s correlation r = 0.121; p = 0.124).
There was a statistically significant relationship ob-
served between nuclear maspin and Ki-67 expression
(p < 0.001). Spearman’s correlation analysis showed a
negative correlation between level of maspin localized in
nucleus and percentage of Ki-67 positive cells (r = 0.771;
p < 0.001). In specimens in which less than 20% of cells
expressed Ki-67, most cells showed moderate or strong
staining intensity of nuclear maspin. Most cases of lack or
weak staining intensity of nuclear maspin were observed
in the second group – more than 20% of Ki-67 positive
cells.
Cell culture model for studies of maspin’s subcellular
fraction anticancer activity
Generation of cancer cells or cancer cell lines with mas-
pin located in cytoplasm or nucleus seemed to be the
best way to evaluate maspin localization influence on
cell proliferation and to compare in vitro results to clin-
ical data. Since the size and the structure of maspin the-
oretically allows maspin to passively diffuse through
nuclear pore complexes (NPCs) (with all possible disad-
vantages of such diffusion taking place), we decided to
use maspin fusion proteins with EGFP. We aimed at
selecting MCF-7 breast cancer cell lines stably express-
ing maspin-EGFP fusion protein as a model for cytoplas-
mic maspin and maspin-NLS-EGFP fusion protein as a
model for nuclear maspin. As an additional control we
intended to select an EGFP protein expressing MCF-7 cell
line. According to our expectations MCF-7 cells trans-
fected with maspin-EGFP construct showed maspin-EGFP
location exclusively in cytoplasm while cells transfected
with maspin-NLS-EGFP construct showed nuclear accu-
mulation of the protein (Figure 3c). A weak signal from
cytoplasm from maspin-NLS-EGFP protein may result
from newly synthesized protein not yet transported into
the nucleus and/or actively stopped in the cytoplasm by
interaction with other proteins. Cells transfected with
EGFP protein showed mixed nuclear and cytoplasmic lo-
cation of this protein (Figure 3c). All of our attempts to
generate stable cell lines expressing maspin-NLS-EGFP
protein failed. All cells died within 2-3 weeks time after
transfection, while we had no problems with selection of
Figure 2 Maspin influence on survival and proliferative status of cells from breast tumor specimens. a, b - Kaplan-Meier analysis of survival
of patients with breast cancer according to the localization and expression level of maspin; nuclear localization and higher level of this maspin
pool positively affect the survival of patients unlike the cytoplasmically localized maspin and its higher level; c, d - correlation between proliferative
status and maspin localization and expression level in breast cancer patients; strong and moderate level of nuclear maspin correlates with smaller
subpopulation of cells expressing Ki-67 (less than 20%) in specimens from patients in contrast to weak expression or lack of nuclear maspin; there
is no significant correlation between cytoplasmic maspin and Ki-67 expression; N = 166.
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and EGFP protein (Figure 3d). This suggested that nuclear
location of maspin is toxic for MCF-7 breast cancer cells
during longer periods of time while cytoplasmic maspin-
bearing cells could survive and proliferate.
Maspin location and proliferation of transfected
MCF-7 cells
Since we failed to select stable cell line expressing
maspin-NLS-EGFP we were forced to perform further
experiments on transiently transfected cells. We decided
to analyze the proliferation rate and phenotype of MCF-
7 cells expressing EGFP protein, cytoplasmic maspin
and nuclear maspin at various time points after transfec-
tion between 24 h and 120 h (1-5 days). Figure 4a,b
demonstrates the typical phenotypes of MCF-7 cells
transiently transfected with plasmids coding for EGFP,
maspin-EGFP and maspin-NLS-EGFP proteins after
48 h and 96 h as the most essential for analyses. At the
first time points (24 – 72 h) cells with cytoplasmicmaspin and nuclear maspin showed similar phenotype
with respect to size and shape (Figure 4a-48 h). At time
points of 72 up to 120 h we started to observe a decrease
in the number of cells expressing Ki-67 protein in MCF-7
cells with nuclear maspin (Figure 4b-96 h). Figure 4c sum-
marizes the general trend observed in analyzed cells ex-
pressing nuclear maspin. Since Ki-67 protein is a marker
of proliferation we analyzed the proliferation rate and per-
formed statistical analyses of Ki-67 protein expression in
transfected MCF-7 cells.
Cell populations of the attached, transfected and non-
transfected cells were daily counted for 9 days and then
the percent of transfected cells in comparison to all cells
was calculated (Figure 5a,b). The efficiency of transfec-
tion in all three cases was about 35% (after 24 hours).
After 48 hours, there was an increase in percentage of
EGFP transfected cells and a decrease in the maspin-
EGFP and maspin-NLS-EGFP subpopulation. From 24
and 48 hours after transfection the percentage of cells ex-
pressing maspin-EGFP and maspin-NLS-EGFP decreased
Figure 3 (See legend on next page.)
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Figure 3 A tissue culture model system for studies of location-dependent maspin’s effect on breast cancer cells. a - pReceiver M03
plasmid map in which the sequence of maspin (NM_002639) was cloned; b - sequences of primers for mutagenesis to the nuclear localization
signal (NLS) insertion; c - transient transfection of MCF-7 cells with three plasmids: pEGFP, Msp-EGFP and Msp-NLS-EGFP, maspin staining pattern
confirms proper localization in transfected cells; d - stable cell lines: MCF-7 EGFP clone 1.2 expressing EGFP, MCF-7 maspin-EGFP clone 3.6 expressing
maspin with fusion protein EGFP localized in cytoplasm; generation of cell line with nucleus-localized maspin failed because of death of all
transfected cells.
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expressing cells between 24 and 48 h was a result of
increased efficiency of production of EGFP protein in
transfected cells above the detection level and a lower
level of overall transfection toxicity.
Until the third day (up to 72 h) after transfection, a
decrease of percent of transfected cells (for all plasmids)
was a net result of cell death and higher proliferation
rate of untransfected cells. After that time, new colonies
expressing transfection marker (EGFP) appeared in
EGFP and maspin-EGFP transfected cells. However,
there was no new colony formation observed in maspin-
NLS-EGFP cells. After the third day, a further decrease
of percent of transfected cells was still mainly caused by
a higher proliferation rate of non-transfected cells.
Significant differences in proliferation were noticeable
separately between EGFP and maspin-EGFP and EGFP
and maspin-NLS-EGFP. Statistically significant differ-
ences between maspin-EGFP and maspin-NLS-EGFP
were observed only at 96 h and 144 h after transfection
(Figure 5b).
We performed statistical analyses of the amount of
cells expressing Ki-67 protein among MCF-7 cells ex-
pressing EGFP and cytoplasmic and nuclear maspin
(Figure 5c,d). We found a strong correlation between
nuclear maspin and disappearance of Ki-67 protein at
time points starting from 72 h. No correlation was found
for cytoplasmic maspin and EGFP protein. This indicates
that nuclear maspin inhibits proliferation of MCF-7
breast cancer cell lines starting from 72 h by mecha-
nisms triggering degradation or inhibition of expression
of Ki-67 protein. This implies that only nuclear but not
cytoplasmic maspin shows this anti-proliferative activity.
These data also are in perfect agreement with the nu-
clear maspin prognostic marker for patients with breast
cancer.Nuclear maspin shows its anti-proliferative activity in
other breast cancer cell lines
In order to analyze the potential benefits for use of nu-
clear maspin as an anti-cancer genetic drug we decided
to use additional breast cancer cell lines. Up to now we
have tested the effect of maspin on MCF-7 breast can-
cer cell line (ER+, PR+, HER2 -). For our next studies
we have chosen SKBR-3 cell line (ER-, PR-, HER2 +)and the highly aggressive, triple negative MDA-MB-231
cell line (ER-, PR-, HER2 -) [36].
In transfected cells, there were no differences in Ki-67
staining pattern in comparison to control cells (Figure 6)
and to the data gathered using MCF-7 cells (Figure 4).
Nuclei morphology was not altered in transfected cells,
but in some cases of cells expressing high levels of nu-
clear maspin, the cell nucleus was larger than in non-
transfected cells. This may indicate polyploidy of these
cells. After 48 h and 72 h, most cells that lost Ki-67 ex-
pression revealed a high level of maspin in the nucleus
(Figure 6).
The analyses of cells revealed, similarly to MCF-7
studies, that only nuclear maspin induces the loss of
Ki-67 protein expression (Figure 6c,f ). The majority of
control, EGFP and maspin-EGFP cells in both cell lines
expressed Ki-67 from 24 h to 120 h after transfection
and the Ki-67 protein staining pattern in these cells
was similar to that of MCF-7 cells. It seems that in
SKBR-3 cells and MDA-MB-231 cells, the loss of Ki-67
expression in cells with nuclear maspin occurs later
after transfection compared to MCF-7. In MCF-7 cell
line, a decrease in Ki-67-positive cells expressing nu-
clear maspin was observed at 72 h after transfection,
while in SKBR-3 and MDA-MB-231 cell lines gradual
loss of Ki-67 expression was noted after 96 h.
Nuclear maspin does not affect proliferation of normal
epithelial cells.
The antiproliferative effect of nuclear maspin on breast
cancer cell lines shows optimistic prospects for use of
nuclear maspin as a potential genetic drug for breast
cancer treatment. In order to test the effect of nuclear
maspin on normal cell proliferation and potential unspe-
cific cytotoxicity for normal breast cells we chose the
epithelial normal cell line MCF10A. This cell line is ER-,
PR- HER2- [36] and expresses maspin which locates
more or less uniformly in the cytoplasm (Figure 7c).
The level of expression of endogenous maspin in this
cell line is several-fold lower than that achieved by tran-
sient expression of maspin using our constructs. Simi-
larly to previous cell lines transfection of MCF10A cells
with EGFP, maspin-EGFP and maspin-NLS-EGFP does
not significantly affect the phenotype of cells. There is
also no difference in number of Ki-67 protein-positive
cells between control cells and those with EGFP,
Figure 4 Analyses of Ki-67 protein expression in MCF-7 cells
with expression of EGFP, maspin-EGFP and maspin-NLS-EGFP.
Cells were transiently transfected with plasmids containing transgenes:
EGFP, maspin-EGFP and maspin-NLS-EGFP. a, b - Cells fixed at 48 h
and 96 h after transfection. a - 48 hours after transfection some cells
expressing high levels of maspin localized in nucleus demonstrate
reduction in Ki-67 protein; b - after 96 hours the subpopulation of cells
with nuclear maspin expressing Ki-67 is decreased; at the same time
there are no significant differences in control cells and cells transfected
with EGFP and maspin-EGFP localized in cytoplasm; c - magnification
of cells with nuclear localization of maspin at 24 to 120 hours after
transfection and gradual loss of Ki-67 protein; arrows show cells
expressing nuclear maspin that lost Ki-67 protein.
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ing the first three days after transfection. After that time
the number of Ki-67 protein positive cells varies in dif-
ferent transfections but changes are not statistically sig-
nificant (Figure 7a, b and d). The decrease in number of
Ki-67 protein-positive cells from 96 h to 120 h is the re-
sult of increased confluence of cells since normal epithe-
lial cells are more susceptible to overpopulation and
contact inhibition than breast cancer cells. We believe
that these higher deviation errors arise from the contact
inhibition since MCF10A control cells (data not shown)
also show similar effects after 96 and 120 h.
The lack of inhibition of proliferation of MCF10A cells
by maspin indicates that antiproliferative activity of nu-
clear maspin is restricted solely to/against breast cancer
cells. This indicates that nuclear maspin may be used as
a genetic drug in breast cancer treatment.Discussion
In many publications the various maspin localization has
been confirmed, including the nuclear localization, which
initially was ignored as an artifact [18,19,37]. Nuclear mas-
pin localization was observed in breast, prostate, lung,
colorectal, pancreas and larynx cancers [19,20,23-26,37].
Even if the anticancer effect of the nuclear fraction of
maspin has been described in some reports, the precise
significance of the maspin expression level and subcellu-
lar localization is still not completely understood. More-
over, recent reports on maspin function have focused on
cytoplasmic maspin or undirected maspin introduction
into the cells, which resulted in its cytoplasmic location
[30,31,37]. Also the biological function of maspin and its
influence on degree of differentiation, stage and invasive-
ness of cancer are not clearly established. Therefore we
decided to investigate the effect of maspin localization
on breast cancer with reference to clinical data from
breast cancer specimens from patients (Figure 1).
Many reports have suggested that biological of maspin
in various types of cancer depend on its subcellular
localization [19-22]. Therefore, maspin protein level was
Figure 5 Statistical analysis of cell proliferation and Ki-67 expression in transfected MCF-7 cells. Control cells and cells transfected with
three plasmids – EGFP, maspin-EGFP and maspin-NLS-EGFP – were subjected to statistical analyses of proliferation and Ki-67 protein expression;
a, b - cell proliferation assay at 24 h to 9 days after transfection; only after 96 h and 144 h were there significant differences between cells expressing
cytoplasmic and nuclear maspin, but generally cells in both transfections died rapidly; however, there were new colonies in MCF-7 msp-EGFP cells, in
contrast to msp-NLS-EGFP cells; c, d - percent of transfected cells expressing Ki-67 protein; there are significant differences at 72 h after transfection
between cells expressing nucleus-localized maspin and those expressing both cytoplasm-localized maspin and EGFP; these differences increase at 96 h
and 120 h after transfection.
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each specimen from patients.
In our study, a positive reaction to maspin was dem-
onstrated in most specimens – 89.2%. A mixed reaction,
localized both in nucleus and cytoplasm, was observed
in most cases; only cytoplasmic localization was ob-
served in 21.1% of cases and only nuclear in 13.3%. Simi-
lar data were obtained in studies in ovarian cancer,
where most cases of low grading tumor exhibited maspin
expression and most of them showed nuclear reaction
[32]. In other studies on breast cancer specimens, about
96% of samples showed nuclear maspin expression and a
cytoplasmic signal was present in 35% of the cases [19].
To evaluate the effect of maspin localization on cell
proliferation, the proliferation status of cells in samples
from patients was determined by immunohistochemical
staining for Ki-67 protein (Figure 1j,k). The expression
of proliferation marker Ki-67 is one of the main indica-
tors of tumor cell proliferation and tumor grading.
Moreover, it is used as a prognostic factor that helps to
predict an outcome of cancer treatment [33,38]. Results
obtained in our study indicated a statistically significantcorrelation between higher level of maspin protein in
nuclei and decreased number of cells expressing Ki-67
(Figure 2c,d). These data suggest that the nuclear frac-
tion of maspin has a strong influence on proliferation
status of breast cancer cells in breast tissue, inhibiting
their growth and division. The cytoplasmic fraction of
maspin seems to have either an opposite effect than the
nuclear pool or have no significant effect on prolifera-
tion status of breast cancer cells. Analyses of the
Kaplan–Meier data indicated that in a time span of 2-
5 years, lack of cytoplasmic maspin is beneficial over
cytoplasmic maspin (Figure 2a,b). Also total lack of mas-
pin is beneficial over low level of nuclear maspin (cumu-
lative survival index 0.7 versus 0.2). The demonstrated
correlation indicates the functional significance of each
pool of maspin and suggests that maspin level and loca-
tion may be considered for use as a prognostic marker
as well.
To validate and compare results obtained in clinical
studies, we decided to establish an in vitro model for
assessing the functional significance of nuclear and cyto-
plasmic localization of maspin in breast cancer cell lines:
Figure 6 (See legend on next page.)
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Figure 6 Analysis of Ki-67 protein expression in MDA-MB-231 and SKBR-3 cells with various localization of maspin. Cells were transiently
transfected with plasmids EGFP, maspin-EGFP and maspin-NLS-EGFP and fixed 24 to 120 hours later; a, b, d, e - the majority of cells transfected
with all three constructs express Ki-67 protein at 48 h and 96 h after transfection; c, f - the majority of cells expressing nucleus-localized maspin
do not express Ki-67 at 120 h after transfection; simultaneously there is no such observation in control cells and cells expressing EGFP and
msp-EGFP localized in cytoplasm; arrows show cells expressing nuclear maspin that lost Ki-67 protein.
Figure 7 Ki-67 protein expression in MCF10A cells with various localization of maspin. Cells were transfected with plasmids EGFP, maspin-EGFP
and maspin-NLS-EGFP and fixed after 24 to 120 hours; a, b - the majority of cells transfected with all three constructs express Ki-67 protein at 48 h and
120 h after transfection; c - maspin localization in MCF10A cells after transfection; MCF10A cell line expresses endogenous maspin which is mostly
localized in cytoplasm; d - statistical analysis of Ki-67 expression in MCF10A cells transfected with three plasmids; there are no significant differences at
24 h to 120 h after transfection between cells expressing nucleus-localized maspin and those expressing both cytoplasm-localized maspin and EGFP.
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mal epithelial cell line MCF10A as a control for normal
breast tissue. These breast cancer cell lines do not ex-
press endogenous maspin because of its silencing mainly
by epigenetic processes: CpG island methylation and his-
tone deacetylation [39,40]. Control, normal cell line
MCF10A does express maspin but at a relative moderate
level and the protein is rather uniformly distributed in
the cytoplasm.
All of the previously used methods of maspin re-
expression or overexpression [32,41,42] in tumors and
breast cancer cell lines had some disadvantages. Classical
cDNA transfection, transduction by adenoviruses, pro-
tein administration and re-expression by artificial tran-
scription factors resulted in cytoplasmic or extracellular
localization of maspin. Such in vitro experimental
models did not address properly the problem of dual
maspin location observed in breast cancer tissues. That
is why our major aim was to develop an easy and appro-
priate model for studies of the effect of differently lo-
cated maspin fractions on breast cancer cell lines.
In order to devise a simple model system allowing for
controlled placement of maspin in cytoplasm and cell nu-
cleus, we used EGFP protein as a fusion tag. EGFP protein
(27 kDa, no NLS and NES signals) alone is capable of two-
way diffusion through nuclear pore complexes [43]. Our
model allows for active transport of maspin with fusion
protein but prevents free diffusion. For driving maspin-
EGFP fusion protein into the cell nucleus we added a NLS
signal sequence in a short linker protein fragment between
maspin and EGFP (Figure 3b) to allow for proper folding
of maspin and the EGFP part of the protein.
Analyses of location of maspin fusion proteins in
MCF-7 cells using confocal microscopy fully supported
our idea of driving maspin fusion proteins to the cyto-
plasm and nucleus using EGFP and NLS (Figure 3c).
In other breast cancer cell lines (SKBR-3 and MDA-
MB-231) the expression level of maspin fusion protein
was similar but the ratio between nuclear and cytoplas-
mic fractions of maspin NLS-EGFP fusion proteins was
a little lower (lower efficiency of maspin placement to tar-
geted location) (Figure 6). This effect may be caused by
maspin retention or active transport by binding/interact-
ing proteins. MCF10A cells show a similar ratio between
the nuclear and cytoplasmic maspin protein (Figure 7c).
When both endogenous and exogenous maspin is ana-
lyzed using antibodies against maspin protein the lower
efficiency of maspin placement to the targeted location
is achieved since endogenous maspin locates in cyto-
plasm (Figure 7c). Thus in transfected MCF10A cells
the level of maspin protein in nuclei is comparable with
all other cancer cell lines tested while cytoplasmic mas-
pin (endogenous and exogenous together) is roughly
about 10-20% higher than in tested cancer cell lines.Taking the observations together, we successfully con-
structed a simple, efficient and complete model to study
the influence of maspin localization on breast cancer cell
growth, which can be used for further studies using tran-
sient transfection.
Usefulness of this model was confirmed during our at-
tempts to select cancer cell lines expressing nuclear
maspin (maspin-NLS-EGFP), which failed completely
and always within 2-3 weeks of selection. Since it was
possible to select many cell lines expressing cytoplasmic
maspin (Figure 3d) this demonstrated from the beginning
the different and anti-proliferative activity of nuclear mas-
pin. However, obtaining clones expressing maspin-EGFP
required a longer period of time and lower concentration
of selection antibiotic (because of cell death) than EGFP
clones. Moreover, after transfection and a couple of days
of selection, there were more EGFP-positive proliferating
clones than in maspin-EGFP, despite the transfection effi-
ciency being similar. Therefore, overexpression of maspin
localized in cytoplasm may lead to slowdown of cell
proliferation.
Nevertheless, there was no evidence that it was caused
directly by a negative effect of cytoplasmic maspin on
cells. It may be a result of overexpression of a larger pro-
tein with some biological functions, whilst EGFP is
smaller and should not interfere with any cellular pro-
cesses. However, previous reports demonstrated that ex-
ogenous maspin protein addition or transfection with
plasmid encoding maspin (cytoplasmic location) resulted
in increased cell sensitivity to cytotoxic agents, increased
cell adhesion and inhibition of proliferation [42,44].
Proliferation assays and Ki-67 protein staining per-
formed on MCF-7 breast cancer cell line indicated that
the antiproliferative activity of maspin is the strongest in
cells with nuclear maspin. For this reason, we have not
been able to generate a stable breast cancer cell line ex-
pressing maspin localized in the nucleus and it does not
allow us for precise studies of signaling pathways trig-
gered by maspin. In the literature, there was no informa-
tion about attempts of generation of a stable cell line
with nuclear maspin, so it seems that this was the very
first attempt to do so. Perhaps the generation of such a
stable cell line will be possible only when maspin-NLS
will be under a strictly controlled inducible promoter.
Anti-proliferative activity of nuclear maspin on MCF-7
cells (Figures 4 and 5) was confirmed on other breast
cancer cell lines: SKBR-3 cells and highly invasive MDA-
MB-231 cell line (Figure 6). This indicates that nuclear
maspin may be used as a prognostic marker and possibly
as a therapeutic agent for cancer treatment using engi-
neered maspin cDNA, for obtaining nuclear location of
maspin, as a genetic drug in gene therapy.
In order to confirm the potential usefulness of nuclear
maspin as a genetic drug we tested its potential negative
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line MCF10A. This normal breast tissue cell line expresses
maspin which is located mostly in cytoplasm (Figure 7c).
Transient expression of maspin did not have any signifi-
cant effect on proliferation of MCF10A cells or the num-
ber of Ki-67 protein expressing cells (Figure 7a,b,d), thus
confirming the high potential of nucleus-directed maspin
as an anticancer agent in gene therapy. But still, the major
question of what is the molecular mechanism of maspin
action remains unanswered.
The major difficulty clouding the biological activity of
maspin is lack of sufficient knowledge of molecular
mechanisms regulating maspin subcellular location in
normal and cancer tissues. In the maspin protein se-
quence, neither characteristic domains nor sequences
which may target maspin to the nucleus were found.
Passive transport to the nucleus is rather unlikely due to
maspin’s weight (42 kDa) and structure. This is verified
experimentally since simple expression of maspin cDNA
in many cancer cells results in cytoplasmic location of
the protein. EGFP (27 kDa) expression results in dual
nucleo-cytoplasmic location.
Many proteins may be translocated to the nucleus as a
result of phosphorylation, for example the transcription
factors IRF (interferon regulatory factors) [45]. Maspin,
in its structure, has many potential phosphorylation
sites. In vitro studies on mammary epithelial cells trans-
fected with maspin indicate that maspin protein is phos-
phorylated by a kinase domain from the epidermal
growth factor receptor (EGFR) [46]. This may regulate
interaction of maspin with its binding partners which in
turn, depending on their function and modifications,
may translocate to and from the cell nucleus, affecting
maspin location. On the other hand, maspin presence in
a particular fraction may modulate the activity of inter-
acting protein.
Proteins that may directly interact with maspin are not
well known, although some studies in recent years suggest
direct interaction of maspin with proteins associated with
oxidative stress (GST – glutathione S-transferase) [47],
heat shock proteins (HSP), histone deacetylase (HDAC1-
histone deacetylase I) [48], and IRF6 (interferon regulatory
factor 6) [48], possibly indirectly affecting function of such
transcription factors as Egr-1 and CGF2 [48]. Moreover,
maspin may indirectly modulate the pro-apoptotic protein
BAX (Bcl-2–associated X protein) [30], increase expres-
sion of the antiangiogenic thrombospondin and affect the
expression of E2F1 [49,50]. Maspin is also implied in in-
crease of expression of proteins from chromatin remodel-
ing complex SMARCA2 and decreased expression of
cytokines inducing inflammation and cell proliferation
[49]. There was also observed maspin association with
chromatin at the promoter of colony-stimulating factor-1
(CSF-1), which caused inhibition of tumor growth [22].Some of these interactions may play an important role in
maspin antiproliferation activity or maspin translocation
to the cell nucleus.
The most interesting crosstalk between breast cancer
cell proliferation and maspin offers two interactions of
maspin: with IRF6 transcription factor and with HDAC1
in a GST-dependent manner. IRF6 promotes changes in
cell adhesion, mobility and cell cycle probably (among
others) through cadherin and vimentin. IRF6 locates
both in cytoplasm and cell nucleus and interacts with
maspin only when it is phosphorylated [51]. Recent
studies demonstrated that IRF phosphorylation and sub-
sequent proteasomal degradation are associated with in-
duction of proliferation in normal breast epithelial cells
(MCF10A). Concomitantly with this in breast cancer cell
lines (MCF-7 and MDA-MD-231) overexpression of
IRF6 together with maspin (located cytoplasmically) in-
duced a synergistic effect of inhibition of proliferation
but not total inhibition of proliferation [52]. This result
resembles our data on proliferation slowdown by cyto-
plasmic maspin (Figure 5a,b).
The second directly interacting partner is HDAC1
complexed with GST. Cytoplasmic maspin may seques-
ter complexes containing HDAC1 and GST and modu-
lating its transport to nucleus and activity. Nuclear
maspin may inhibit HDAC1 in a GST-dependent man-
ner (oxidative stress sensitive) and prevent chromatin re-
modeling and change in transcription in an oxidative
dependent manner [28].
The intriguing question is whether the loss of Ki-67
protein in cells with nuclear maspin is the cause or the
result of the anti-proliferative effect of nuclear maspin
on cells. The presence of Ki-67 protein is commonly
used as a proliferation marker but its cellular functions
are diverse and complex. During interphase it plays a
crucial role in structural organization of nuclei, tran-
scription and splicing of ribosomal RNA. The function
of Ki-67 protein during mitosis is not fully understood
but it belongs to the group of chromosomal passenger
proteins and is located on mitotic chromosomes during
mitosis [33,38]. Moreover, Ki-67 is necessary for forming
a proper connection between microtubules and chromo-
some and for correct mitosis [53]. The time frame of cell
death of nuclear maspin-containing cells fits exactly the
3-day interval between loss of Ki-67 protein (72 h) and
cell death (144 h) (Figures 4, 5, and 6).
Exogenous and cytoplasmic maspin may increase cell
adhesion by activation of ERK1/2 and MAP kinases and
independently the PI3K pathway (through atypical
PKCzeta) and inhibit cell mobility by inhibition of Rac1
and PAK1 pathways. Increased cell adhesion may cause
inhibition of cell proliferation [31,54]. Therefore, overex-
pression of maspin localized in cytoplasm may lead to
slowdown of cell proliferation, which may explain why
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plasmic maspin) slow down proliferation but do not stop
proliferating. Unfortunately, current knowledge of mas-
pin does not provide any sufficient explanations for the
function of nuclear maspin in complete blocking of pro-
liferation of breast cancer cell lines in our model system.
Since we also demonstrated that nuclear maspin is cru-
cial for better prognosis and inhibition of proliferation
of breast tumors in vivo it suggests that nuclear maspin
may be successfully used as a prognostic marker and po-
tential genetic drug for gene therapy for breast cancer.
Conclusions
Our results indicate that nuclear maspin localization
may be a prognostic factor in breast cancer and may
have a strong therapeutic potential. High level of nuclear
maspin is associated with better survival among breast
cancer patients and lower proliferation status; thus nu-
clear maspin can be considered as a new marker of good
prognosis of breast cancer. We also observed the inhibi-
tory effect of nuclear maspin on cell proliferation
in vitro in the three most frequently used breast cancer
cell line models (MCF-7, SKBR-3 and MDA-MB-231),
while there was no effect on proliferation of normal
MCF10A breast cells. Maspin localization in the cell nu-
cleus correlates with consecutive loss of Ki-67 protein,
cell proliferation inhibition and cell death. Our data sug-
gest a strong potential of nuclear maspin in breast can-
cer gene therapy treatment and provide a new insight
into the role of maspin in breast cancer.
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